Risk factors for endoscopic ultrasound-guided radiofrequency ablation adverse events in patients with pancreatic neoplasms: a large national French study (RAFPAN study).

Date publication

avril 2023

Journal

Gastrointestinal endoscopy

Auteurs

Membres identifiés du Cancéropôle Est :
Dr HABERSETZER François , Dr VUITTON Lucine

Tous les auteurs :
Napoléon B, Lisotti A, Caillol F, Gasmi M, Ah-Soune P, Belle A, Charachon A, Cholet F, Eyraud PY, Grandval P, Gonzalez JM, Habersetzer F, Koch S, Le Rhun M, Mangialavori L, Musquer N, Palazzo M, Poincloux L, Privat J, Sportes A, Stouvenot M, Subtil C, Thomassin L, Vanbiervliet G, Vidal G, Vuitton L, Giovannini M, Barthet M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37059368

Résumé

Endoscopic ultrasound radiofrequency ablation (EUS-RFA) has been described as a potentially curative option for solid and cystic pancreatic neoplasms. We aimed to assess the safety and efficacy of pancreatic EUS-RFA in a large study population.

Mots clés

IPMN, Insulinoma, Wirsung, endocrine neoplasm, metastasis, pancreatic cancer, radiofrequency ablation

Référence

Gastrointest Endosc. 2023 04 12;: